Can belantamab mafodotin be used in patients with renal impairment?

DREAMM-2: Single-Agent Belantamab Mafodotin in Patients with RRMM and Renal ImpairmentПодробнее

A real-world analysis of belantamab mafodotin in patients with R/R multiple myelomaПодробнее

Managing and treating renal impairment in multiple myelomaПодробнее

Impact of prior therapies on efficacy of belantamab mafodotin in R/R myelomaПодробнее

All About BLENREP (Belantamab Mafodotin-blmf)Подробнее

DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patientsПодробнее

Causes & management of renal impairment in patients with multiple myelomaПодробнее

Belantamab mafodotin in R/R myeloma and methods of reducing ocular toxicityПодробнее

What is GSK 2857916, also known as belantamab mafodotin?Подробнее

DREAMM-2 & DREAMM-5: belantamab mafodotin for myelomaПодробнее

Belantamab mafodotin: ocular toxicityПодробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

Cost Effectiveness Comparison of Belantamab Mafodotin and Selinexor in RRMMПодробнее

EMN 27: Phase II study of belantamab mafodotin in patients with R/R AL amyloidosisПодробнее

DREAMM-3: belantamab mafodotin vs pom/dex for R/R myelomaПодробнее

Surrogate markers in patients with R/R myeloma receiving belantamab mafodotinПодробнее

Belantamab mafodotin for myeloma: Phase 1 data & patient-reported outcomesПодробнее

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dex in RRMMПодробнее

DREAMM-2: update on belantamab mafodotin in R/R myelomaПодробнее